Zacks: Analysts Anticipate Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) to Post -$0.28 Earnings Per Share

Equities analysts forecast that Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) will announce earnings of ($0.28) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Neoleukin Therapeutics’ earnings, with estimates ranging from ($0.29) to ($0.26). Neoleukin Therapeutics reported earnings of ($0.18) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 55.6%. The firm is expected to report its next quarterly earnings report on Monday, November 8th.

On average, analysts expect that Neoleukin Therapeutics will report full-year earnings of ($1.13) per share for the current financial year, with EPS estimates ranging from ($1.20) to ($1.06). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.37) per share, with EPS estimates ranging from ($1.78) to ($1.13). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Neoleukin Therapeutics.

Neoleukin Therapeutics (NASDAQ:NLTX) last announced its quarterly earnings data on Thursday, August 5th. The company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.01).

A number of equities analysts have commented on NLTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Neoleukin Therapeutics in a report on Monday, August 9th. Zacks Investment Research cut shares of Neoleukin Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday.

In other news, CEO Jonathan G. Drachman purchased 100,000 shares of Neoleukin Therapeutics stock in a transaction dated Tuesday, August 24th. The stock was acquired at an average cost of $6.11 per share, for a total transaction of $611,000.00. Following the acquisition, the chief executive officer now directly owns 2,348,686 shares in the company, valued at $14,350,471.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.90% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC lifted its holdings in shares of Neoleukin Therapeutics by 399.9% during the second quarter. Cubist Systematic Strategies LLC now owns 5,499 shares of the company’s stock worth $51,000 after buying an additional 4,399 shares during the last quarter. Metropolitan Life Insurance Co NY grew its holdings in shares of Neoleukin Therapeutics by 98,600.0% during the second quarter. Metropolitan Life Insurance Co NY now owns 9,870 shares of the company’s stock worth $91,000 after purchasing an additional 9,860 shares during the last quarter. UBS Asset Management Americas Inc. bought a new stake in shares of Neoleukin Therapeutics during the second quarter worth $95,000. Royal Bank of Canada grew its holdings in shares of Neoleukin Therapeutics by 14.6% during the first quarter. Royal Bank of Canada now owns 9,483 shares of the company’s stock worth $117,000 after purchasing an additional 1,209 shares during the last quarter. Finally, Invesco Ltd. bought a new stake in shares of Neoleukin Therapeutics during the second quarter worth $130,000. Hedge funds and other institutional investors own 63.57% of the company’s stock.

NASDAQ:NLTX traded up $0.23 during trading hours on Wednesday, hitting $7.28. The stock had a trading volume of 106,152 shares, compared to its average volume of 210,904. Neoleukin Therapeutics has a 1-year low of $5.95 and a 1-year high of $17.95. The business has a 50 day simple moving average of $7.22 and a two-hundred day simple moving average of $9.28. The company has a market cap of $308.85 million, a PE ratio of -8.88 and a beta of 0.97.

Neoleukin Therapeutics Company Profile

Neoleukin Therapeutics, Inc operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

Further Reading: What are the Benefits of Index Funds?

Get a free copy of the Zacks research report on Neoleukin Therapeutics (NLTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neoleukin Therapeutics (NASDAQ:NLTX)

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.